Results 181 to 190 of about 154,909 (319)

Antigen‐Targeting Inserted Nanomicelles Guide Pre‐Existing Immunity to Kill Head and Neck Cancer

open access: yesAdvanced Science, EarlyView.
This study introduces a tumor‐targeted nanomicelle platform (preS1‐pHLIP) that exploits pre‐existing antiviral immunity to combat heterogeneous cancers. By delivering viral antigens to label tumors as virus‐like targets, the nanomicelles activate antiviral B and T cells, triggering in situ tumor lysis.
Lizhuo Zhang   +16 more
wiley   +1 more source

HNF3α Targets Nckap1l and Promotes Renal Fibrosis Following Ischemia‐Reperfusion Injury

open access: yesAdvanced Science, EarlyView.
Hepatocyte Nuclear Factor 3 alpha (HNF3α) is significantly upregulated in renal tubular epithelial cells of CKD patients and fibrotic mice. Deletion of HNF3α mitigates IRI‐induced renal fibrosis, while overexpression worsens it. HNF3α directly regulates NCK‐associated protein 1‐like (Nckap1l), whose overexpression exacerbates fibrosis.
Ling Hou   +7 more
wiley   +1 more source

Chemotherapy‐Mediated Induction of PD‐L1 via SEI1 Facilitates Myeloma Immune Evasion

open access: yesAdvanced Science, EarlyView.
Chemotherapy induces DNA damage, activating cyclic guanosine monophosphate (GMP)‐adenosine monophosphate (AMP) synthase (cGAS)/stimulator of interferon genes (STING), which phosphorylates interferon regulatory factor 7 (IRF7) to drive SERTA‐containing domain 1 (SEI1) transcription.
Rui Chen   +9 more
wiley   +1 more source

PRMT1 Ablation in Endothelial Cells Causes Endothelial Dysfunction and Aggravates COPD Attributable to Dysregulated NF‐κB Signaling

open access: yesAdvanced Science, EarlyView.
This study investigates the role of protein arginine methyltransferase 1 (PRMT1) in endothelial cells (ECs) in chronic obstructive pulmonary disease (COPD). Mice with endothelial‐specific PRMT1 deletion develop pulmonary hemorrhage, inflammation, and apoptosis, driven by excessive nuclear factor kappa B activation.
Thi Thuy Vy Tran   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy